Brief: NanoCarrier says orphan drug designation of NC-6004 by the U.S. FDA

Nano Holdings

01/08/2017 03:45

Aug 1 (Reuters) - NanoCarrier Co Ltd  4571.T   
     
     
    * Says NC-6004, which is under development in the U.S. for 
biliary cancer, has been granted to the orphan drug designation 
from the U.S. FDA (Food and Drug Administration) 
     
    Source text in Japanese:https://goo.gl/xiDDk8 
    Further company coverage: 4571.T  
 
 (Beijing Headline News) 
 ((Beijing.HeadlineNews@thomsonreuters.com; +8601082555111; 
Reuters Messaging: Pingping.Li1@thomsonreuters.com@reuters.net))